<DOC>
	<DOC>NCT00171977</DOC>
	<brief_summary>This is a multicenter, post-marketing, clinical study evaluating the safety and efficacy of postoperative adjuvant therapy with Imatinib Mesylate in high-risk patients after curative resection of newly diagnosed GIST.Patients will be evaluated for relapse -free survival as measured by the confirmation of tumor recurrence and survival for 3 years after surgery for their primary tumors.</brief_summary>
	<brief_title>Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>underwent macroscopically curative resection; immunohistochemically confirmed KIT (CD117)positive tumors; judged as being highrisk according to the criteria for risk classification synchronous double cancer or metachronous double cancer with a diseasefree period of â‰¤5 years; received therapy with Imatinib Mesylate prior to study entry; cardiac problem of Grade 3 or higher (New York Heart Association (NYHA) criteria) Other protocoldefined inclusion / exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>GIST</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Postoperative Adjuvant</keyword>
</DOC>